Clinical trial NCT00243893: Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms
Official title: Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Aneurysms
Arteriovenous Malformations
Keywords: giant aneurysms
arteriovenous malformations
minocycline
doxycycline
BAVM
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: National Institute of Neurological Disorders and Stroke (NINDS)
First posted: 2005-10-25
Enrollment: 26
Sex: ALL
Minimum age (years): 13
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this pilot study is to investigate the use of minocycline and doxycycline as medical therapy for inoperable or partially treated arteriovenous malformations (AVMs) and giant aneurysms.

Detailed description: Arteriovenous malformations (AVMs) are a treatable cause of stroke in young adults. The processes by which AVMs and giant aneurysms grow in size and spontaneously bleed are unknown. The primary reason to treat AVMs and aneurysms is to guard against intracranial bleeding.

This pilot study will examine the use of two common antibiotics-minocycline and doxycycline-as medical therapy for inoperable or partially treated AVMs and giant aneurysms. These drugs, which are tetracycline derivatives, can reduce the levels of a family of enzymes, called matrix metalloproteases, that degrade tissue and thereby cause a reduction in the risk of spontaneous bleeding from AVMs or aneurysm-which is the main cause of stroke associated with these disorders. The enzymes can contribute to weaknesses in the wall of blood vessels and may increase the risk of the vessel wall rupturing and causing spontaneous bleeding.

This trial also will show that taking minocycline and doxycycline over an extended period in this patient population is safe and well tolerated. Results from this study could help plan future studies to benefit patients with abnormal blood vessels prone to bleeding in their brains.

Eligibility criteria: Inclusion Criteria:

* Giant aneurysms or brain arteriovenous malformations (BAVM)
* Female patients of child bearing age using effective birth control, males
* Creatinine no greater than 2.0 mg/dl
* ALT no greater than 2 times upper limit of control

Exclusion Criteria:

* Unstable medical illness
* Contraindications to Tetracycline
* History of vestibular disease, (except benign positional vertigo)
* Prior tetracycline use within 2 mos of baseline visit.
* History of noncompliance with treatment or other protocols
* History of systemic lupus
* Patients not eligible for MRI

Primary outcomes:
measure: MRI will be done baseline and post treatment.
timeFrame: 2 years
measure: MMP levels are being followed q 6-mos.
timeFrame: Patients called weekly for 1st-3 months, then every 6-months until completion of study
measure: Drug levels are being followed q 6-mos.
timeFrame: Patients called weekly for 1st-3 months, then every 6-months until completion of study
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California
state: California
Study officials:
affiliation: University of California, San Francisco
name: William L. Young, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T, Lawton MT, Guglielmo BJ, McCulloch CE, Young WL. Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance. Cerebrovasc Dis. 2008;25(1-2):157-63. doi: 10.1159/000113733. Epub 2008 Jan 23.